Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Validation and Detection of Exon Skipping Boosters in DMD Patient Cell Models and mdx Mouse.

Barthelemy F, Wang D, Nelson SF, Miceli MC.

Methods Mol Biol. 2018;1828:309-326. doi: 10.1007/978-1-4939-8651-4_19.

PMID:
30171550
2.

DMD genotype correlations from the Duchenne Registry: Endogenous exon skipping is a factor in prolonged ambulation for individuals with a defined mutation subtype.

Wang RT, Barthelemy F, Martin AS, Douine ED, Eskin A, Lucas A, Lavigne J, Peay H, Khanlou N, Sweeney L, Cantor RM, Miceli MC, Nelson SF.

Hum Mutat. 2018 Sep;39(9):1193-1202. doi: 10.1002/humu.23561. Epub 2018 Jul 12.

3.

Repurposing Dantrolene for Long-Term Combination Therapy to Potentiate Antisense-Mediated DMD Exon Skipping in the mdx Mouse.

Wang DW, Mokhonova EI, Kendall GC, Becerra D, Naeini YB, Cantor RM, Spencer MJ, Nelson SF, Miceli MC.

Mol Ther Nucleic Acids. 2018 Jun 1;11:180-191. doi: 10.1016/j.omtn.2018.02.002. Epub 2018 Feb 13.

4.

Lectin-binding characterizes the healthy human skeletal muscle glycophenotype and identifies disease-specific changes in dystrophic muscle.

McMorran BJ, Miceli MC, Baum LG.

Glycobiology. 2017 Dec 1;27(12):1134-1143. doi: 10.1093/glycob/cwx073.

5.

A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy.

Victor RG, Sweeney HL, Finkel R, McDonald CM, Byrne B, Eagle M, Goemans N, Vandenborne K, Dubrovsky AL, Topaloglu H, Miceli MC, Furlong P, Landry J, Elashoff R, Cox D; Tadalafil DMD Study Group.

Neurology. 2017 Oct 24;89(17):1811-1820. doi: 10.1212/WNL.0000000000004570. Epub 2017 Sep 29.

6.

FDA Approval of Eteplirsen for Muscular Dystrophy.

Nelson SF, Miceli MC.

JAMA. 2017 Apr 11;317(14):1480. doi: 10.1001/jama.2017.2601. No abstract available.

PMID:
28399245
7.

Baseline Shoulder Ultrasonography Is Not a Predictive Marker of Response to Glucocorticoids in Patients with Polymyalgia Rheumatica: A 12-month Followup Study.

Miceli MC, Zoli A, Peluso G, Bosello S, Gremese E, Ferraccioli G.

J Rheumatol. 2017 Feb;44(2):241-247. doi: 10.3899/jrheum.160090. Epub 2016 Dec 15.

PMID:
27980012
8.

The case for eteplirsen: Paving the way for precision medicine.

Miceli MC, Nelson SF.

Mol Genet Metab. 2016 Jun;118(2):70-1. doi: 10.1016/j.ymgme.2016.04.001. Epub 2016 Apr 14. No abstract available.

PMID:
27102846
9.

Osteopontin ablation ameliorates muscular dystrophy by shifting macrophages to a pro-regenerative phenotype.

Capote J, Kramerova I, Martinez L, Vetrone S, Barton ER, Sweeney HL, Miceli MC, Spencer MJ.

J Cell Biol. 2016 Apr 25;213(2):275-88. doi: 10.1083/jcb.201510086. Epub 2016 Apr 18.

10.

A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-Derived Muscle Cells.

Young CS, Hicks MR, Ermolova NV, Nakano H, Jan M, Younesi S, Karumbayaram S, Kumagai-Cresse C, Wang D, Zack JA, Kohn DB, Nakano A, Nelson SF, Miceli MC, Spencer MJ, Pyle AD.

Cell Stem Cell. 2016 Apr 7;18(4):533-40. doi: 10.1016/j.stem.2016.01.021. Epub 2016 Feb 11.

11.

Discs Large Homolog 1 Splice Variants Regulate p38-Dependent and -Independent Effector Functions in CD8+ T Cells.

Silva O, Crocetti J, Humphries LA, Burkhardt JK, Miceli MC.

PLoS One. 2015 Jul 17;10(7):e0133353. doi: 10.1371/journal.pone.0133353. eCollection 2015.

12.

De novo nonsense mutations in KAT6A, a lysine acetyl-transferase gene, cause a syndrome including microcephaly and global developmental delay.

Arboleda VA, Lee H, Dorrani N, Zadeh N, Willis M, Macmurdo CF, Manning MA, Kwan A, Hudgins L, Barthelemy F, Miceli MC, Quintero-Rivera F, Kantarci S, Strom SP, Deignan JL; UCLA Clinical Genomics Center, Grody WW, Vilain E, Nelson SF.

Am J Hum Genet. 2015 Mar 5;96(3):498-506. doi: 10.1016/j.ajhg.2015.01.017. Epub 2015 Feb 26.

13.

Selective phosphorylation of the Dlg1AB variant is critical for TCR-induced p38 activation and induction of proinflammatory cytokines in CD8+ T cells.

Crocetti J, Silva O, Humphries LA, Tibbs MD, Miceli MC.

J Immunol. 2014 Sep 15;193(6):2651-60. doi: 10.4049/jimmunol.1401196. Epub 2014 Aug 6.

14.

PDE5 inhibition alleviates functional muscle ischemia in boys with Duchenne muscular dystrophy.

Nelson MD, Rader F, Tang X, Tavyev J, Nelson SF, Miceli MC, Elashoff RM, Sweeney HL, Victor RG.

Neurology. 2014 Jun 10;82(23):2085-91. doi: 10.1212/WNL.0000000000000498. Epub 2014 May 7.

15.

Body weight, gender and response to TNF-α blockers in axial spondyloarthritis.

Gremese E, Bernardi S, Bonazza S, Nowik M, Peluso G, Massara A, Tolusso B, Messuti L, Miceli MC, Zoli A, Trotta F, Govoni M, Ferraccioli G.

Rheumatology (Oxford). 2014 May;53(5):875-81. doi: 10.1093/rheumatology/ket433. Epub 2014 Jan 9.

PMID:
24407233
16.

Dantrolene enhances antisense-mediated exon skipping in human and mouse models of Duchenne muscular dystrophy.

Kendall GC, Mokhonova EI, Moran M, Sejbuk NE, Wang DW, Silva O, Wang RT, Martinez L, Lu QL, Damoiseaux R, Spencer MJ, Nelson SF, Miceli MC.

Sci Transl Med. 2012 Dec 12;4(164):164ra160. doi: 10.1126/scitranslmed.3005054.

17.

Characterization of in vivo Dlg1 deletion on T cell development and function.

Humphries LA, Shaffer MH, Sacirbegovic F, Tomassian T, McMahon KA, Humbert PO, Silva O, Round JL, Takamiya K, Huganir RL, Burkhardt JK, Russell SM, Miceli MC.

PLoS One. 2012;7(9):e45276. doi: 10.1371/journal.pone.0045276. Epub 2012 Sep 18.

18.

Caveolin-1 orchestrates TCR synaptic polarity, signal specificity, and function in CD8 T cells.

Tomassian T, Humphries LA, Liu SD, Silva O, Brooks DG, Miceli MC.

J Immunol. 2011 Sep 15;187(6):2993-3002. doi: 10.4049/jimmunol.1101447. Epub 2011 Aug 17.

19.

Galectin-1-induced down-regulation of T lymphocyte activation protects (NZB x NZW) F1 mice from lupus-like disease.

Liu SD, Lee S, La Cava A, Motran CC, Hahn BH, Miceli MC.

Lupus. 2011 Apr;20(5):473-84. doi: 10.1177/0961203310388444. Epub 2011 Feb 18.

PMID:
21335401
20.

A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis.

Giardina AR, Ferrante A, Ciccia F, Impastato R, Miceli MC, Principato A, Triolo G.

Rheumatol Int. 2010 Sep;30(11):1437-40. doi: 10.1007/s00296-009-1157-3. Epub 2009 Oct 23.

PMID:
19851772
21.

Emerging genetic therapies to treat Duchenne muscular dystrophy.

Nelson SF, Crosbie RH, Miceli MC, Spencer MJ.

Curr Opin Neurol. 2009 Oct;22(5):532-8. doi: 10.1097/WCO.0b013e32832fd487. Review.

22.

Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta.

Vetrone SA, Montecino-Rodriguez E, Kudryashova E, Kramerova I, Hoffman EP, Liu SD, Miceli MC, Spencer MJ.

J Clin Invest. 2009 Jun;119(6):1583-94. doi: 10.1172/JCI37662. Epub 2009 May 18.

23.

Galectin-1 tunes TCR binding and signal transduction to regulate CD8 burst size.

Liu SD, Tomassian T, Bruhn KW, Miller JF, Poirier F, Miceli MC.

J Immunol. 2009 May 1;182(9):5283-95. doi: 10.4049/jimmunol.0803811.

24.

Galectin-1 functions as a Th2 cytokine that selectively induces Th1 apoptosis and promotes Th2 function.

Motran CC, Molinder KM, Liu SD, Poirier F, Miceli MC.

Eur J Immunol. 2008 Nov;38(11):3015-27. doi: 10.1002/eji.200838295.

25.

Endogenous galectin-1 enforces class I-restricted TCR functional fate decisions in thymocytes.

Liu SD, Whiting CC, Tomassian T, Pang M, Bissel SJ, Baum LG, Mossine VV, Poirier F, Huflejt ME, Miceli MC.

Blood. 2008 Jul 1;112(1):120-30. doi: 10.1182/blood-2007-09-114181. Epub 2008 Mar 6.

26.

Scaffold protein Dlgh1 coordinates alternative p38 kinase activation, directing T cell receptor signals toward NFAT but not NF-kappaB transcription factors.

Round JL, Humphries LA, Tomassian T, Mittelstadt P, Zhang M, Miceli MC.

Nat Immunol. 2007 Feb;8(2):154-61. Epub 2006 Dec 24.

PMID:
17187070
27.

Dlgh1 coordinates actin polymerization, synaptic T cell receptor and lipid raft aggregation, and effector function in T cells.

Round JL, Tomassian T, Zhang M, Patel V, Schoenberger SP, Miceli MC.

J Exp Med. 2005 Feb 7;201(3):419-30.

28.

CD45 signals outside of lipid rafts to promote ERK activation, synaptic raft clustering, and IL-2 production.

Zhang M, Moran M, Round J, Low TA, Patel VP, Tomassian T, Hernandez JD, Miceli MC.

J Immunol. 2005 Feb 1;174(3):1479-90.

29.

TCR-mediated hyper-responsiveness of autoimmune Galphai2(-/-) mice is an intrinsic naïve CD4(+) T cell disorder selective for the Galphai2 subunit.

Huang TT, Zong Y, Dalwadi H, Chung C, Miceli MC, Spicher K, Birnbaumer L, Braun J, Aranda R.

Int Immunol. 2003 Nov;15(11):1359-67.

PMID:
14565934
30.

TCR signal transduction in antigen-specific memory CD8 T cells.

Kersh EN, Kaech SM, Onami TM, Moran M, Wherry EJ, Miceli MC, Ahmed R.

J Immunol. 2003 Jun 1;170(11):5455-63.

PMID:
12759421
31.

Clusters, bundles, arrays and lattices: novel mechanisms for lectin-saccharide-mediated cellular interactions.

Brewer CF, Miceli MC, Baum LG.

Curr Opin Struct Biol. 2002 Oct;12(5):616-23. Review.

PMID:
12464313
32.

Activation of CD8 T cells induces expression of CD4, which functions as a chemotactic receptor.

Kitchen SG, LaForge S, Patel VP, Kitchen CM, Miceli MC, Zack JA.

Blood. 2002 Jan 1;99(1):207-12.

33.

Co-stimulation and counter-stimulation: lipid raft clustering controls TCR signaling and functional outcomes.

Miceli MC, Moran M, Chung CD, Patel VP, Low T, Zinnanti W.

Semin Immunol. 2001 Apr;13(2):115-28. Review.

PMID:
11308295
35.

Galectin-1 induces partial TCR zeta-chain phosphorylation and antagonizes processive TCR signal transduction.

Chung CD, Patel VP, Moran M, Lewis LA, Miceli MC.

J Immunol. 2000 Oct 1;165(7):3722-9.

36.

Galectin-1 specifically modulates TCR signals to enhance TCR apoptosis but inhibit IL-2 production and proliferation.

Vespa GN, Lewis LA, Kozak KR, Moran M, Nguyen JT, Baum LG, Miceli MC.

J Immunol. 1999 Jan 15;162(2):799-806.

38.

The Lck SH2 phosphotyrosine binding site is critical for efficient TCR-induced processive tyrosine phosphorylation of the zeta-chain and IL-2 production.

Lewis LA, Chung CD, Chen J, Parnes JR, Moran M, Patel VP, Miceli MC.

J Immunol. 1997 Sep 1;159(5):2292-300.

PMID:
9278318
39.
40.

Role of CD4 and CD8 in T cell activation and differentiation.

Miceli MC, Parnes JR.

Adv Immunol. 1993;53:59-122. Review. No abstract available.

PMID:
8512039
41.

Extensive polymorphism in the extracellular domain of the mouse B cell differentiation antigen Lyb-2/CD72.

Robinson WH, Ying H, Miceli MC, Parnes JR.

J Immunol. 1992 Aug 1;149(3):880-6.

PMID:
1634777
42.

The roles of CD4 and CD8 in T cell activation.

Miceli MC, Parnes JR.

Semin Immunol. 1991 May;3(3):133-41. Review.

PMID:
1909592
43.

Adhesion versus coreceptor function of CD4 and CD8: role of the cytoplasmic tail in coreceptor activity.

Miceli MC, von Hoegen P, Parnes JR.

Proc Natl Acad Sci U S A. 1991 Apr 1;88(7):2623-7.

44.

Enhancement of T-cell responsiveness by the lymphocyte-specific tyrosine protein kinase p56lck.

Abraham N, Miceli MC, Parnes JR, Veillette A.

Nature. 1991 Mar 7;350(6313):62-6.

PMID:
1706070
45.

Equivalence of human and mouse CD4 in enhancing antigen responses by a mouse class II-restricted T cell hybridoma.

von Hoegen P, Miceli MC, Tourvieille B, Schilham M, Parnes JR.

J Exp Med. 1989 Dec 1;170(6):1879-86.

46.

[Epidemiologic data on breast feeding in Florence and the province. Survey carried out in 1364 children born between 1985 and 1987].

Calzolari C, Miceli MC, Sacchetti A, Santetti I, Vitali E, Panero C, Cianciulli D, Carbone C, Fasulo A.

Pediatr Med Chir. 1989 Nov-Dec;11(6):653-6. Italian.

PMID:
2636379
47.

Effector T-cell repertoire selection in human allograft rejection.

Finn OJ, Miceli MC.

Transplant Proc. 1989 Feb;21(1 Pt 1):346-8. No abstract available.

PMID:
2495608
48.

T cell receptor beta-chain selection in human allograft rejection.

Miceli MC, Finn OJ.

J Immunol. 1989 Jan 1;142(1):81-6.

PMID:
2535861
49.

Role of CD4 and CD8 in enhancing T-cell responses to antigen.

Parnes JR, von Hoegen P, Miceli MC, Zamoyska R.

Cold Spring Harb Symp Quant Biol. 1989;54 Pt 2:649-55. No abstract available.

PMID:
2518008
50.

Supplemental Content

Loading ...
Support Center